Opendata, web and dolomites

PULTAR

Delivery of PULmonary Therapeutics through TARgetted Delivery using Phononics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 PULTAR project word cloud

Explore the words cloud of the PULTAR project. It provides you a very rough idea of what is the project "PULTAR" about.

mu    transits    anatomical    model    substantial    team    start    outcomes    patients    reduce    lungs    dalys    amount    monodisperse    quality    diseases    worldwide    cells    nebulisation    selective    genes    mouse    inhalation    industry    clinical    healthcare    tissue    respiratory    lung    innovation    routes    sizes    therapy    people    precise    nebuliser    treating    generally    forms    cystic    rna    according    drug    pulmonary    regions    appealing    therapeutic    million    disease    treatment    limitations    aerosol    create    64m    efficacy    arterial    380b    shown    similarly    proprietary    gene    3m    wisdom    vascular    droplets    droplet    market    asthma    again    data    accepted    commercial    medicine    difficult    gt    therapies    chronic    235    barriers    prototype    delivered    hypertension    biologics    suffer    types    closely    50m    deaths    medicines    aerosols    epithelium    improves    ultrasonic    enhanced    extremely    obstructive    strand    fibrosis   

Project "PULTAR" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITY OF GLASGOW 

Organization address
address: UNIVERSITY AVENUE
city: GLASGOW
postcode: G12 8QQ
website: www.gla.ac.uk

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country United Kingdom [UK]
 Total cost 149˙791 €
 EC max contribution 149˙791 € (100%)
 Programme 1. H2020-EU.1.1. (EXCELLENT SCIENCE - European Research Council (ERC))
 Code Call ERC-2014-PoC
 Funding Scheme ERC-POC
 Starting year 2015
 Duration (year-month-day) from 2015-07-01   to  2016-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITY OF GLASGOW UK (GLASGOW) coordinator 149˙791.00

Map

 Project objective

According to the WHO 235 million people suffer from asthma and 64M people have chronic obstructive pulmonary disease, leading to 3M deaths per year worldwide. The cost of treating patients with all forms of lung disease is ~ €380B p.a., leading to the loss of >50M DALYS. Generally, patients with such respiratory diseases are treated by inhalation of medicines within aerosols, where the therapy (including medicine or biologics used in gene therapy) can be targeted directly to the lung. The accepted wisdom is that such pulmonary delivery requires aerosol droplet sizes of between 1 and 5 μm. We have now shown that by using a new ultrasonic technology, we can create monodisperse aerosol droplets, which could be used for therapeutic delivery of medicines, genes and RNA to specific regions in the lungs. In one strand of the work we aim to demonstrate that this precise nebulisation technology improves the efficacy of treatment through enhanced drug uptake. In a second strand, we will demonstrate selective targeting of different tissue types in the lungs. For example, the epithelium in cystic fibrosis patients is currently extremely difficult to access leading to limitations in the amount and quality of data obtained for pre-clinical and clinical gene therapies. Similarly, targeting vascular cells is an appealing treatment for patients with pulmonary arterial hypertension, although, again, effective delivery necessitates that the therapeutic system transits defined and substantial anatomical barriers. The overall aim is to demonstrate that this new technology can define routes to new therapies, improve clinical outcomes and reduce healthcare costs. To achieve this we will develop a prototype nebuliser based upon proprietary technology and show that different medicines and gene therapies can be delivered effectively to the lungs of a model mouse. We will also start to build a commercial team and work closely with industry to deliver impact and innovation to the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "PULTAR" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "PULTAR" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.1.)

ImmUne (2019)

Towards identification of the unifying principles of vertebrate adaptive immunity

Read More  

MuFLOART (2018)

Microbiological fluorescence observatory for antibiotic resistance tracking

Read More  

ModGravTrial (2019)

Modified Gravity on Trial

Read More